CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
第一代 CD19 CAR-T 细胞在 B 细胞恶性肿瘤中的临床疗效证据
英文原题：Evidence of clinical efficacy of a first generation CD19 CAR T cell in B cell malignancies.
查看英文原题
Evidence of clinical efficacy of a first generation CD19 CAR T cell in B cell malignancies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
加入共刺激结构域可增强 CAR-T 细胞的持久性和反应性，这是目前已获批 CAR-T 细胞疗法的基础，但代价是细胞因子释放效应增强、毒性上升。这是首篇关于仅含单一活化结构域的抗 CD19 CAR-T 细胞疗法的报告，显示其安全性特征良好且具有临床疗效；在一组经多线治疗的 B 细胞恶性肿瘤患者中，两例患者获得了持久缓解，最长达 28 个月。
展开英文摘要原文
The persistence and reactivity of CAR T cells were enhanced by adding co-stimulatory domains, which is the basis of currently approved CAR-T cell therapies.
However, this comes at the expense of increasing toxicities from the strong cytokine release effect. This is the first report from anti-CD19 CAR-T cell therapy with a single activation domain to show a favourable safety profile and clinical efficacy with two patients who achieved durable responses up to 28 months in a cohort with heavily pretreated B cell malignancies.
论文信息
- 作者
- Shohdy KS、Pillai M、Guest R、Rothwell D、Kirillova N、Chow S、Gilham D、Thistlethwaite F
- 单位
- Division of Cancer Sciences The University of Manchester and The Christie NHS Foundation Trust Manchester UK.United Kingdom
- 期刊
- EJHaem2023 Aug
- 原文标识
- PubMed 37601889 · DOI 10.1002/jha2.731
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →